Skip to main content

A randomized phase II study of adjuvant Trastuzumab emtansine (T-DM1) vs Paclitaxel in combination with Trastuzumab for stage I HER2-positive breast cancer (ATEMPT Trial)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Dana-Farber Cancer Institute

Start Date

June 1, 2014

End Date

December 31, 2022
 

Administered By

Duke Cancer Institute

Awarded By

Dana-Farber Cancer Institute

Start Date

June 1, 2014

End Date

December 31, 2022